Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain Ekterly Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentColorado Rocky Mountain Health PlansPolicy N/A

    Ekterly (sebetralstat) for Acute Hereditary Angioedema Attacks

    Customize your policy alerts

    Sign up for all Colorado Rocky Mountain Health Plans policy alerts

    Know when Colorado Rocky Mountain Health Plans releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity requirements for Ekterly in adult and pediatric members aged 12 years and older with hereditary angioedema. It applies to providers seeking initial authorization or reauthorization for acute HAE treatment.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyEkterly (sebetralstat) for Acute Hereditary Angioedema Attacks
    Policy CodePolicy N/A
    Change TypeAnnual review — no material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming qualifying HAE, required prior-treatment history, noncombination use, and prescribing by an immunologist or allergist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Age 12+Minimum age indicated for Ekterly treatment
    12 monthsInitial authorization duration
    12 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Reauthorization duration
    2Eligible prescribing specialties
    NoneCoverage changes in annual review

    Coverage Criteria

    Initial authorization

    Covered when all of the following initial authorization criteria are met.

    threshold":"Age >=18 years","children":[]}]},{"operator":"any","label":"Prescriber specialty","text":"The prescriber is an immunologist or allergist.","children":[{"operator":"all","label":"Immunologist","text":"The prescriber is an immunologist.","children":[]},{"operator":"all","label":"Allergist","text":"The prescriber is an allergist.","children":[]}]}]}

    Reauthorization

    Covered when all reauthorization criteria are met.

    • Clinical response: Documentation shows a positive clinical response to Ekterly therapy.
    • Treatment use: Ekterly is prescribed for the acute treatment of HAE attacks and is not used in combination with another product indicated for the acute treatment of HAE attacks, including Berinert, Firazyr, icatibant, Kalbitor, Ruconest, or Sajazir.
    • Prescriber specialty

      • Immunologist: The prescriber is an immunologist.
      • Allergist: The prescriber is an allergist.

    Ekterly must not be used in combination with another product indicated for the acute treatment of hereditary angioedema (HAE) attacks, including Berinert, Firazyr, icatibant, Kalbitor, Ruconest, or Sajazir.

    Ekterly and brand Firazyr are typically excluded from coverage. Verify the member’s plan-specific exclusion status before submitting a request. Plan-specific tried/failed requirements or other benefit limitations may apply. For members younger than 18, documentation must show failure, contraindication, or intolerance to Berinert or Ruconest. For members 18 years or older, documentation must show failure, contraindication, or intolerance to both one of those C1 esterase inhibitor products and icatibant (generic Firazyr).

    Provider Actions and Authorization Guidance

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for Ekterly. Initial approval requires all applicable diagnosis, prior-treatment, prescribing, and acute-use criteria to be met; authorization is issued for 12 months.

    • Ekterly must be prescribed for the acute treatment of hereditary angioedema (HAE) attacks.
    • Ekterly must not be used in combination with another product indicated for acute HAE treatment, including Berinert, Firazyr/icatibant, Kalbitor, Ruconest, or Sajazir.
    • The prescriber must be an immunologist or allergist.
    Prior Authorization

    Annual Reauthorization

    Annual reauthorization is required every 12 months. Continued approval requires documentation that the member is responding positively to Ekterly and that ongoing use remains consistent with the acute-treatment and prescribing requirements.

    • Authorization will be issued for 12 months.
    • The member must continue to use Ekterly for acute HAE attacks and not in combination with another acute HAE treatment.

    Policy Background

    Ekterly (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema. This policy applies to adult and pediatric members aged 12 years and older with HAE, including HAE associated with C1-inhibitor deficiency or dysfunction and qualifying HAE with normal C1-inhibitor levels. Prior authorization and medical-necessity requirements apply to initial authorization and reauthorization for acute HAE treatment.

    Hereditary Angioedema Definitions

    Type I or Type II HAE
    DefinitionHereditary angioedema with C1 inhibitor (C1-INH) deficiency or dysfunction, including Type I or Type II HAE.
    C1-INH antigenic levelBelow the lower limit of normal, per laboratory standard.
    C1-INH functional levelBelow the lower limit of normal, per laboratory standard.
    HAE with normal C1 inhibitor levels
    C1 inhibitor levelsNormal.
    Qualifying genetic variantsConfirmed variant(s) in factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-sulfotransferase 6.
    Clinical attacks with family history

    Initial Therapy

    Initial authorization

    Initial therapy is covered when all diagnosis, treatment-use, age-specific prior-treatment, and prescriber-specialty requirements are met.

    Initial therapy

    • Diagnosis of hereditary angioedema

      • C1-INH deficiency or dysfunction: The patient has Type I or Type II HAE, with either a C1-INH antigenic level or C1-INH functional level below the lower limit of normal, per laboratory standard.Below lower limit of normal
      • HAE with normal C1 inhibitor levels

        • Qualifying pathway: The patient has a confirmed variant in factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-O-sulfotransferase 6; or recurrent angioedema attacks refractory to high-dose antihistamines with a confirmed family history of angioedema; or recurrent angioedema attacks refractory to high-dose antihistamines with unknown background de-novo mutation(s) and no family history.

    Continuation Therapy

    Reauthorization

    Reauthorization is covered when all of the following criteria are met.

    Continuation therapy

    • Positive clinical response: Documentation shows a positive clinical response to Ekterly therapy.
    • Acute HAE treatment: Ekterly continues to be prescribed for the acute treatment of HAE attacks.
    • No combination use: Ekterly is not used in combination with another product indicated for the acute treatment of HAE attacks, including Berinert, Firazyr, icatibant, Kalbitor, Ruconest, or Sajazir.
    • Prescriber specialty

    Age-Based Step Therapy

    Member ageStep-therapy requirement
    Younger than 18 yearsDocumented failure, contraindication, or intolerance to Berinert or Ruconest.
    18 years or olderDocumented failure, contraindication, or intolerance to both one of the following: Berinert or Ruconest; and icatibant (generic Firazyr).
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyEkterly (sebetralstat) for Acute Hereditary Angioedema Attacks
    Policy CodePolicy N/A
    Change TypeAnnual review — no material change
    Effective DateNov 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming qualifying HAE, required prior-treatment history, noncombination use, and prescribing by an immunologist or allergist.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization GuidancePolicy BackgroundHereditary Angioedema DefinitionsInitial TherapyContinuation TherapyAge-Based Step Therapy
  1. The prescriber must be an immunologist or allergist.
  2. Step Therapy

    Age-Specific HAE Product Trial Requirement

    Age-specific prior treatment must be documented before initial approval. The required HAE product trials differ for members younger than 18 years and adults.

    • Members younger than 18: medical records must document failure, contraindication, or intolerance to Berinert or Ruconest.
    • Members 18 or older: medical records must document failure, contraindication, or intolerance to both one of Berinert or Ruconest and icatibant (generic Firazyr).
    Documentation Required

    Initial Clinical Documentation

    Submit clinical records confirming HAE and supporting the applicable diagnosis pathway. Documentation must include laboratory, genetic, family-history, and attack-history evidence as applicable.

    • For Type I or II HAE, document C1-INH deficiency or dysfunction with a C1-INH antigenic level below the laboratory lower limit of normal or a C1-INH functional level below the laboratory lower limit of normal.
    • For HAE with normal C1-INH levels, document either a confirmed variant in the factor XII, angiopoietin-1, plasminogen-1, kininogen-1, myoferlin, or heparan sulfate-glucosamine 3-Osulfotransferase 6 gene; recurring attacks refractory to high-dose antihistamines with a confirmed family history of angioedema; or recurring attacks refractory to high-dose antihistamines with no known family history consistent with HAEunknown.
    • Include relevant attack history, family history, laboratory results, and genetic testing or other supporting records.
    Documentation Required

    Reauthorization Documentation

    For reauthorization, submit records demonstrating a positive clinical response to Ekterly and continued need for its authorized use.

    • Document positive clinical response to Ekterly therapy.
    • Document continued use for the acute treatment of HAE attacks.
    Denial Risk

    Failure to Meet Initial Authorization Criteria

    Initial authorization may be denied when any required initial criterion is not met or adequately documented.

    • HAE diagnosis is not confirmed through the required laboratory, genetic, family-history, or attack-history pathway.
    • Ekterly is not prescribed for acute HAE attacks, is planned in combination with another acute HAE product, or is prescribed by someone other than an immunologist or allergist.
    • Required age-specific failure, contraindication, or intolerance to prior HAE products is absent or not supported by medical records.
    Denial Risk

    Failure to Meet Reauthorization Criteria

    Continuation authorization may be denied when the member does not demonstrate ongoing clinical benefit or no longer meets the acute-treatment and prescribing requirements.

    • Positive clinical response to Ekterly is not documented.
    • Continued acute HAE use is not documented, or Ekterly is being used in combination with another product indicated for acute HAE treatment.
    • The prescriber is not an immunologist or allergist.
    Billing Rule

    Plan Exclusions and Benefit Limitations

    Plan-specific benefit limitations may affect coverage even when clinical criteria are met. Ekterly and brand Firazyr are typically excluded from coverage, and tried/failed requirements may apply.

    • Confirm the member-specific benefit plan and exclusion status before submitting or dispensing.
    • Review plan-specific tried/failed requirements and other applicable utilization-management policies.
    • State mandates, federal regulatory requirements, member benefit coverage, and other policies may also affect coverage.
    Recurrent angioedema attacks refractory to high-dose antihistamines, with a confirmed family history of angioedema.
    Clinical attacks without family historyRecurrent angioedema attacks refractory to high-dose antihistamines, with unknown background de-novo mutation(s) and no family history.
    HAEunknown
    C1 inhibitor levelsNormal.
    Recurrent attacksRecurrent angioedema attacks.
    Antihistamine responseAttacks are refractory to high-dose antihistamines.
    Genetic and family-history criteriaUnknown background de-novo mutation(s), meaning no family history of angioedema.
  3. Treatment use: Ekterly is prescribed for the acute treatment of HAE attacks and is not used in combination with another product indicated for the acute treatment of HAE attacks, including Berinert, Firazyr, icatibant, Kalbitor, Ruconest, or Sajazir.
  4. Age-specific prior treatment

    • Patients younger than 18: The patient is younger than 18 years of age, and medical records document failure, contraindication, or intolerance to Berinert or Ruconest.Age <18 years
    • Patients 18 or older: The patient is 18 years of age or older, and medical records document failure, contraindication, or intolerance to both one of Berinert or Ruconest and icatibant (generic Firazyr).Age >=18 years
  5. Prescriber specialty

    • Immunologist: The prescriber is an immunologist.
    • Allergist: The prescriber is an allergist.
  6. Immunologist: The prescriber is an immunologist.
  7. Allergist: The prescriber is an allergist.